Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.
Freeman MP1, Papakostas GI2, Hoeppner B2, Mazzone E2, Judge H2, Cusin C2, Mathew S3, Sanacora G4, Iosifescu D5, DeBattista C6, Trivedi MH7, Fava M2.
J Psychiatr Res. 2019 Jan 8;110:166-171. doi: 10.1016/j.jpsychires.2019.01.010.
Sex Differences in Response to Ketamine as A Rapidly Acting Intervention for Treatment Resistant Depression
Marlene P.Freemana | George Papakostasa | Bettina Hoeppnera | Erica Mazzonea | Heidi Judgea | Cristina Cusina | Sanjay Mathew | Gerard Sanacorac | Dan Iosifescud | Charles DeBattistae | Madhukar H.Trivedif | Maurizio Favaa
Received 19 September 2018, Revised 3 January 2019, Accepted 7 January 2019, Available online 8 January 2019.
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression
Salloum NC, Fava M, Freeman MP, et al. Efficacy of intravenous ketamine treatment in anxious
versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2018;1–9. https://doi.org/10.1002/da.22875
Received: 23 July 2018 Revised: 3 October 2018 Accepted: 1 December 2018
Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).
Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI.
Brain Stimul. 2018 Jan – Feb;11(1):75-84. doi: 10.1016/j.brs.2017.09.010. Epub 2017 Sep 23.
Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement.
Dodd S, Mitchell PB, Bauer M, Yatham L, Young AH, Kennedy SH, Williams L, Suppes T, Lopez Jaramillo C, Trivedi MH, Fava M, Rush AJ, McIntyre RS, Thase ME, Lam RW, Severus E, Kasper S, Berk M.
World J Biol Psychiatry. 2017 Oct 6:1-19. doi: 10.1080/15622975.2017.1379609. [Epub ahead of print]
From depression to anxiety, and back.
Bui E, Fava M.
Acta Psychiatr Scand. 2017 Oct;136(4):341-342. doi: 10.1111/acps.12801. Epub 2017 Sep 2. No abstract available.
Lessons Learned From the VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) Study.
Fava M.
JAMA. 2017 Jul 11;318(2):126-128. doi: 10.1001/jama.2017.8030. No abstract available.
Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients.
Targum SD, Burch DJ, Asgharnejad M, Petersen T, Gomeni R, Fava M.
Eur Neuropsychopharmacol.2014 Jun 17. pii: S0924-977X(14)00171-0. doi: 10.1016/j.euroneuro.2014 Aug; 24(8):1188-1195.
Circulating microRNAs as biomarkers for depression: Many candidates, few finalists.
Yuan H, Mischoulon D, Fava M, Otto MW.
J Affect Disord. 2017 Jun 27. pii: S0165-0327(16)32446-6. doi: 10.1016/j.jad.2017.06.058. [Epub ahead of print] Review.
Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies.
Fava M, Weiller E, Zhang P, Weiss C.
J Clin Psychopharmacol. 2017 Apr;37(2):276-278. doi: 10.1097/JCP.0000000000000678. No abstract available.
